

**Table 5 - Prevalence of the Metabolic Syndrome in GEMCAS according to different definitions by age and sex**

Age-Group	TotalN	Changes compared to NCEP/ATP-III:										IDF/AHA 2005	$\Delta^{\ddagger}$ %
		NCEP/ATP-III 2001		NCEP/ATP-III mod. <sup>1</sup>		AHA/NHLBI 2004 <sup>*</sup>		AHA/NHLBI 2005 <sup>*</sup>		IDF 2005			
		%	SD	%	SD	%	SD	%	SD	%	SD		
<b>All</b>													
18-29	3541	4.3	0.20	4.4	0.21	4.5	0.21	4.8	0.21	5.9	0.24	1.23	1.11
30-39	4472	8.6	0.28	9.0	0.29	9.5	0.29	10.6	0.31	12.7	0.33	1.20	2.15
40-49	7173	13.1	0.34	14.0	0.35	15.3	0.36	17.5	0.38	20.2	0.40	1.16	2.73
50-59	7404	22.4	0.42	24.7	0.43	27.4	0.45	32.8	0.47	38.0	0.49	1.16	5.18
60-69	5586	30.5	0.46	33.1	0.47	36.2	0.48	45.6	0.50	51.8	0.50	1.14	6.26
70-79	4017	34.9	0.48	38.6	0.49	41.9	0.49	53.1	0.50	58.9	0.49	1.11	5.73
80-99	1116	31.9	0.47	36.3	0.48	39.2	0.49	48.4	0.50	53.0	0.50	1.10	4.67
<b>total</b>	<b>33502</b>	<b>19.8</b>	<b>0.40</b>	<b>21.6</b>	<b>0.41</b>	<b>23.5</b>	<b>0.42</b>	<b>28.6</b>	<b>0.45</b>	<b>32.7</b>	<b>0.47</b>		
<b>total<sup>‡</sup></b>		<b>18.7</b>	<b>0.54</b>	<b>20.3</b>	<b>0.55</b>	<b>22.0</b>	<b>0.57</b>	<b>26.9</b>	<b>0.61</b>	<b>30.7</b>	<b>0.63</b>	<b>1.14</b>	<b>4.07</b>
$\kappa^{\S}$				0.96		0.91		0.80		0.68			
$\kappa^{\parallel}$										0.85			
<b>Men</b>													
18-29	1197	5.4	0.23	5.4	0.23	5.5	0.23	6.0	0.24	7.6	0.27	1.28	1.64
30-39	1510	11.5	0.32	12.0	0.33	13.0	0.34	14.5	0.35	18.3	0.39	1.27	3.87
40-49	2471	16.8	0.37	17.8	0.38	19.9	0.40	24.5	0.43	28.7	0.45	1.17	4.23
50-59	2974	27.3	0.45	29.9	0.46	33.4	0.47	41.5	0.49	48.7	0.50	1.17	7.14
60-69	2463	31.0	0.46	34.0	0.47	37.9	0.49	49.4	0.50	56.3	0.50	1.14	6.95
70-79	1771	32.2	0.47	36.4	0.48	39.8	0.49	51.9	0.50	58.8	0.49	1.13	6.88
80-99	383	26.1	0.44	31.4	0.46	34.2	0.48	45.8	0.50	52.0	0.50	1.14	6.19
<b>total</b>	<b>12838</b>	<b>22.7</b>	<b>0.42</b>	<b>24.9</b>	<b>0.43</b>	<b>27.5</b>	<b>0.45</b>	<b>34.8</b>	<b>0.48</b>	<b>40.3</b>	<b>0.49</b>		
<b>total<sup>‡</sup></b>		<b>19.5</b>	<b>0.61</b>	<b>21.2</b>	<b>0.63</b>	<b>23.3</b>	<b>0.65</b>	<b>29.2</b>	<b>0.70</b>	<b>34.1</b>	<b>0.73</b>	<b>1.16</b>	<b>5.57</b>
$\kappa^{\S}$				0.96									
$\kappa^{\parallel}$										0.79			

Age-Group	TotalN	Changes compared to NCEP/ATP-III: hypertensive treatment included    glucose cut off reduced    drug treatment introduced    Increased waist required and waist cut off reduced										IDF/AHA 2005	$\Delta^{\ddagger}$ %
		NCEP/ATP-III 2001		NCEP/ATP-III mod. <sup>1</sup>		AHA/NHLBI 2004*		AHA/NHLBI 2005*		IDF 2005			
		%	SD	%	SD	%	SD	%	SD	%	SD		
<b>Women</b>													
18-29	2344	3.8	0.19	3.9	0.19	4.0	0.20	4.2	0.20	5.0	0.22	1.20	0.84
30-39	2962	7.2	0.26	7.5	0.26	7.8	0.27	8.6	0.28	9.8	0.30	1.15	1.25
40-49	4702	11.1	0.31	12.1	0.33	12.9	0.33	13.8	0.35	15.8	0.36	1.14	1.97
50-59	4430	19.1	0.39	21.2	0.41	23.4	0.42	27.0	0.44	30.8	0.46	1.14	3.87
60-69	3123	30.2	0.46	32.4	0.47	34.9	0.48	42.6	0.49	48.3	0.50	1.13	5.7
70-79	2246	36.9	0.48	40.4	0.49	43.5	0.50	54.1	0.50	58.9	0.49	1.09	4.84
80-99	733	35.0	0.48	38.9	0.49	41.8	0.49	49.7	0.50	53.6	0.50	1.08	3.89
<b>total</b>	<b>20664</b>	<b>18.0</b>	<b>0.38</b>	<b>19.6</b>	<b>0.40</b>	<b>21.0</b>	<b>0.41</b>	<b>24.8</b>	<b>0.43</b>	<b>28.0</b>	<b>0.45</b>		
<b>total<sup>‡</sup></b>		<b>18.0</b>	<b>0.49</b>	<b>19.5</b>	<b>0.50</b>	<b>20.9</b>	<b>0.51</b>	<b>24.8</b>	<b>0.55</b>	<b>27.7</b>	<b>0.57</b>	<b>1.13</b>	<b>3.12</b>
$\kappa^{\S}$				0.96		0.92		0.83		0.74			
$\kappa^{\parallel}$										0.89			

<sup>1</sup> Modification of the original NCEP/ATP-III-definition, considering subjects using hypertensive medication as having MetSyn

\* often cited as NCEP ATP III-definition

<sup>†</sup> AHA 2005-IDF 2005

<sup>‡</sup> age standardized according to German population (destatis 2005)

<sup>§</sup> kappa of accordance between prevalence of NCEP/ATP-III and following definitions

<sup>||</sup> kappa of accordance between prevalence of AHA/NHLBI (2005) and IDF-definition